NCT07021976

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

A Multicentre, Randomized, Double-blind, Placebo-parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of HRS-1893 Tablets in the Treatment of Obstructive Hypertrophic Cardiomyopathy

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 216 (estimated)
• Sponsor: Shandong Suncadia Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.

Conditions

• Obstructive Hypertrophic Cardiomyopathy

Interventions

Type	Name	Description
DRUG	HRS-1893 Tablets	HRS-1893 tablets.
DRUG	HRS-1893 Placebo Tablets	HRS-1893 placebo tablets.

Timeline

• Start date: 2025-08-11
• Primary completion: 2026-09-01
• Completion: 2026-11-01
• First posted: 2025-06-15
• Last updated: 2025-08-20

Locations

1 site across 1 country: China